Company news

Sino Biopharmaceutical Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly return of equity issuer on movements in securities for the month ended 31 October 2026

November 1, 2026

Voluntary announcement - tq-A3334 "TLR7 agonist" and TQA3605 "core protein allosteric modulator" granted breakthrough therapy designation by cde

October 26, 2026

Voluntary announcement - data from two clinical studies of TQB2102 "HER2 biparatopic adc" presented at 2026 esmo

October 25, 2026

Next day disclosure return

October 22, 2026

Voluntary announcement - completion of all participants enrollment in the phase iii registrational clinical trial of TQC2731 injection "tslp monoclonal antibody" for chronic sinusitis with nasal polyps

October 20, 2026

Voluntary announcement - latest research results on tq-A3334 "TLR7 agonist" and bepirovirsen "aso" to be presented at 2026 aasld

October 14, 2026

Next day disclosure return

October 14, 2026

Next day disclosure return

October 13, 2026

Voluntary announcement - completion of all subjects enrollment in the phase iii registrational clinical trial of TQC3721 inhalation suspension "PDE3/4 inhibitor"

October 8, 2026

Monthly return of equity issuer on movements in securities for the month ended 30 September 2026

October 1, 2026

Voluntary announcement - enter into strategic biosimilars partnership with STADA

September 28, 2026

Notification letter and request form for non-registered shareholders

September 24, 2026

Notification letter and reply form for registered shareholders

September 24, 2026

2026 Interim report

September 24, 2026

Voluntary announcement - acceptance of new drug application for TQH2722 injection

September 15, 2026

Voluntary announcement - acceptance of new drug application for TQB2102 injection "HER2 bispecific adc"

September 15, 2026

Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion

August 19, 2026

Once-Yearly Dosing, Targeting Cardiovascular Disorders, First US Patient Enrolled in China-US Phase II Clinical Trial of Hygieia's Kylo-11

April 9, 2026

Sino Biopharm Releases 2025 Annual Results: Revenue and Net Profit Maintain Double-Digit Growth, Innovative Product Revenue Exceeds RMB 15 Billion

March 26, 2026

Positive on Dual Endpoints! CTTQ Pharma's Phase III Study of TQB3454 in Bile Duct Cancer Succeeds, Marketing Application to be Submitted

March 12, 2026

JPM 2026 | Sino Biopharm Leads in siRNA and Tumor Innovation Platforms, M&A Integration Unleashes Long-Term Growth Momentum

January 15, 2026

Sino Biopharmaceutical: World's First CDK2/4/6 Inhibitor Approved for Marketing, Culmerciclib Capsules (Saitanxin®) Reshape the Breast Cancer Treatment Landscape

December 11, 2025

Phrontline Biopharma Raises $60 Million in Pre-A+ Financing to Advance Global Development of Bispecific and Dual-Payload ADCs

November 24, 2025

MediTrust Health and Sino Biopharm Sign Strategic Cooperation Agreement at CIIE 2025 to Advance Drug-Insurance Integration New Model

November 10, 2025

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

October 30, 2025

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

October 16, 2025

Biopharm 2025 Interim Results Announcement

August 18, 2025

Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial

May 5, 2025

Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results

August 13, 2024

2023 Environmental, social and governance report

April 29, 2024

Sino Biopharm (1177.HK) Announces 2023 Annual Results

March 29, 2024

Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results

August 25, 2023

2022 Environmental, social and governance report

June 8, 2023

Sino Biopharm (1177.HK) Announces 2022 Annual Results

March 31, 2023

Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion

August 23, 2022

Sino Biopharmaceutical: Voluntary announcement - "lenvatinib mesilate capsule" obtains drug registration certificate

July 26, 2021

Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic

July 22, 2021

2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion

May 24, 2021

Voluntary announcement - "palonosetron hydrochloride injection" passes consistency evaluation

May 13, 2021

Voluntary announcement - "dasatinib tablet" passes consistency evaluation

May 12, 2021

Voluntary announcement - appointment of chief medical officer

May 10, 2021

Notification of board meeting

May 3, 2021

Sino Biopharmaceutical: Voluntary announcement - "tian neng" obtains registration certificate of formula food for special medical purpose

April 29, 2021

Voluntary announcement - "su qian" obatains registration certificate of formula food for special medical purpose

April 28, 2021

Voluntary announcement - penpulimab obtained breakthrough therapy designation from FDA for third-line treatment of metastatic nasopharyngeal carcinoma

March 29, 2021

Decks

The 5 newest of 9 decks. Every deck is listed under its year.